Cargando…
The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design
Casein kinase II (CK2) is an ubiquitous and pleiotropic serine/threonine protein kinase able to phosphorylate hundreds of substrates. Being implicated in several human diseases, from neurodegeneration to cancer, the biological roles of CK2 have been intensively studied. Upregulation of CK2 has been...
Autor principal: | Cozza, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374430/ https://www.ncbi.nlm.nih.gov/pubmed/28230762 http://dx.doi.org/10.3390/ph10010026 |
Ejemplares similares
-
The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation
por: Cozza, Giorgio, et al.
Publicado: (2015) -
Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design
por: Chen, Xiaolan, et al.
Publicado: (2020) -
Rational drug-design approach supported with thermodynamic studies — a peptide leader for the efficient bi-substrate inhibitor of protein kinase CK2
por: Winiewska-Szajewska, Maria, et al.
Publicado: (2019) -
The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131
por: Vilardell, Jordi, et al.
Publicado: (2018) -
In Silico-Guided Rational Drug Design
and Semi-synthesis of C(2)-Functionalized Huperzine A Derivatives
as Acetylcholinesterase Inhibitors
por: Anukanon, Shisanupong, et al.
Publicado: (2021)